Granisol ™ (Granisetron) oral solution eligible for Medicaid reimbursement

Current article ratings:
Patients / public:healthcare Prof:
PediatRx, Inc. (OTCBB: PEDX) announced that the U.S. Centers for Medicare and Medicaid Services (CMS) before recently Medicaid notified authorities of to include PediatRx's GRANISOL, NDC 52547-0801-30, in their list of the refunded products. CMS funded jointly with the Governments of the Medicaid and State children health insurance programs. These programs provide health insurance, including prescription drug coverage to more than 40 million families with low income, * and that number is expected to grow legislation with the implementation of the health care reform.

Dr. Cameron Durrant, founder who PediatRx, said: "we are pleased, have reached an agreement with CMS of to include PediatRx's on the list of reimbursed products for Medicaid GRANISOL." "This means that individual State Medicaid programs their formulas, enabling the patients in Medicaid access to the only once-daily oral solution in the Granisetron now can add GRANISOL."

CMS provided in his announcement of PediatRx two dates, the more effective: an optional expiration date 17 March 2011, and a mandatory effective date of 1 July 2011. States can GRANISOL their choice between these two dates at any time start. Patients and health care providers can contact their State Medicaid program to determine whether GRANISOL has been added to the current time. Will find here.

Durrant went on: "we are aware of the financial pressure on patients, including those not state-funded healthcare programs are eligible for funding or uninsured or underinsured." "That is why we developed a program of co-pay, GRANI cares to support GRANISOL for patients."

For patients who are enrolled in Medicaid or Medicare, visit GRANI cares: see here.

GRANISOL is for the prevention of specified:

-Übelkeit and vomiting with first and repeat courses of emetogenic cancer therapy, including high-dose cisplatin.

-Radiation, including whole-body irradiation and fractionated abdominal radiation associated with nausea and vomiting.

Selected security advisories

-GRANISOL is contraindicated in patients with known hypersensitivity to the drug or its components.

-QT prolongation reported with Granisetron. Therefore, GRANISOL should be oral solution in carefully with patients with pre-existing arrhythmias and cardiac conduction errors, be used, because this could lead to clinical consequences. Patients with cardiac disease to heart circulation toxic chemotherapy with concurrent Electrolyte abnormalities and/or accompanying drugs which prolong the QT interval are particularly at risk.

Security and effectiveness in pediatric patients were not identified.

-The most common side effects were observed with the administration of Granisetron headache, asthenia, constipation, diarrhea, dyspepsia, and abdominal pain.

* 2009 U.S. Census Bureau.

Source:
PediatRx, Inc.